top of page
MENU
MENU
News Release
PURMX Therapeutics Initiates Phase I Clinical Trial of MIRX002, a Novel MicroRNA-Based Anticancer Drug, for Head and Neck Cancer
PURMX Therapeutics, Inc. (hereinafter referred to as “PURMX”) (Head Office: 1-2-3 Kasumi, Minami-ku, Hiroshima City, Hiroshima...
2 hours ago
Raised funds through a third-party allocation of new shares from Keio Innovation Initiative, Inc.
PURMX Therapeutics, Inc. (PURMX Therapeutics; Headquarters: Hiroshima, Japan; President: Hidetoshi Tahara; hereafter “the Company”) is...
May 7, 2024
PURMX Therapeutics Raised Funds through a Third-party Allotment of New Shares from Yokohama Capital
We are pleased to announce that PURMX Therapeutics, Inc. (headquartered in Hiroshima City, Japan; Hidetoshi Tahara, President & CEO;...
Nov 30, 2023
bottom of page